# OnCo record paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012" ;
  schema:name "COMFORT-II: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis"@en ;
  schema:description "In this European trial, ruxolitinib shrank the spleen by more than a third in 28 percent of people with myelofibrosis after 48 weeks while no patient on the best alternative treatment achieved that, and symptoms and quality of life improved."@en ;
  schema:url <https://onco.cc/key-papers/paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1110556>, <https://pubmed.ncbi.nlm.nih.gov/22375970/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1110556> ;
  schema:datePublished "2012"^^xsd:gYear ;
  schema:author "Harrison C, Kiladjian JJ, Al-Ali HK, et al." ;
  onco:cancers <https://onco.cc/cancers/primary-myelofibrosis/>, <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:drugs <https://onco.cc/drugs/ruxolitinib/> ;
  onco:trials <https://onco.cc/trials/comfort-ii/> ;
  onco:journals <https://onco.cc/journals/nejm/> .